Beltraminelli, TimDe Palma, Michele2020-05-142020-05-142020-05-142020-04-0110.1002/path.5403https://infoscience.epfl.ch/handle/20.500.14299/168726WOS:000529190600009Macrophages sustain tumour progression by facilitating angiogenesis, promoting immunosuppression, and enhancing cancer cell invasion and metastasis. They also modulate tumour response to anti-cancer therapy in pre-clinical models. This knowledge has motivated the development of agents that target tumour-associated macrophages (TAMs), some of which have been investigated in early clinical trials. Here, we provide a comprehensive overview of the biology and therapeutic targeting of TAMs, highlighting opportunities, setbacks, and new challenges that have emerged after a decade of intense translational and clinical research into these multifaceted immune cells. (c) 2020 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.OncologyPathologyOncologyPathologymacrophagemonocytetumour microenvironmenttherapeutic targetingclinical trialendothelial growth-factorpancreatic ductal adenocarcinomaepithelial ovarian-cancerdelta t-cellsbreast-cancerextracellular vesiclesinfiltrating macrophagesimmune cellsgm-csfinflammatory microenvironmenttext::journal::journal article::review article